This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Small, E. J. Articles by Vogelzang, N. J. Search for Related Content PubMed PubMed Citation Articles by Small, E. J. Articles by Vogelzang, N. J.

Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee

Authors' Affiliations: ¹ University of California/San Francisco, San Francisco, California; ² Cancer and Leukemia Group B Statistical Center, Duke University, Durham, North Carolina; ³ Dana-Farber Cancer Institute, Boston Massachusetts; ⁴ University of Chicago, Chicago, Illinois; ⁵ Yale University, New Haven, Connecticut; ⁶ Roswell Park Cancer Institute, Buffalo, New York; ⁷ Memorial Sloan Kettering Cancer Center, New York, New York; and ⁸ Nevada Cancer Institute, Las Vegas, Nevada

Requests for reprints: Eric J. Small, Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115. Fax: 415-353-7779; E-mail: smalle{at}medicine.ucsf.edu.

The Cancer and Leukemia Group B Genitourinary (GU) Committee has developed a multidisciplinary approach to treatment of GU cancer and has integrated correlative science research into the major research themes of the GU Committee. In localized prostate cancer, trials have evaluated novel approaches in radiation therapy. For patients with recurrence after local therapy, a trial evaluating local recurrence with salvage prostatectomy and a study of systemic therapy with "peripheral androgen blockade" were undertaken. Major contributions have been made in developing and testing therapeutics for advanced, androgen-independent prostate cancer (ketoconazole, suramin, estramustine/docetaxel, and docetaxel/bevacizumab), and in developing predictive markers and algorithms to assess prognosis in these patients. Contributions in kidney cancer have included the development of novel trial methodology, such as the randomized discontinuation trial design, and the testing of antiangiogenics. In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients.